These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180 [TBL] [Abstract][Full Text] [Related]
25. Cancer immunotherapy by fusions of dendritic cells and tumor cells. Koido S; Hara E; Homma S; Ohkusa T; Gong J; Tajiri H Immunotherapy; 2009 Jan; 1(1):49-62. PubMed ID: 20635973 [TBL] [Abstract][Full Text] [Related]
26. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses. Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391 [TBL] [Abstract][Full Text] [Related]
27. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire. Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329 [TBL] [Abstract][Full Text] [Related]
28. Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression. Verma V; Kim Y; Lee MC; Lee JT; Cho S; Park IK; Min JJ; Lee JJ; Lee SE; Rhee JH Oncotarget; 2016 Jun; 7(26):39894-39906. PubMed ID: 27223090 [TBL] [Abstract][Full Text] [Related]
29. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination. Collignon A; Perles-Barbacaru AT; Robert S; Silvy F; Martinez E; Crenon I; Germain S; Garcia S; Viola A; Lombardo D; Mas E; Béraud E Oncotarget; 2015 Sep; 6(27):23462-79. PubMed ID: 26405163 [TBL] [Abstract][Full Text] [Related]
30. Dendritic cell, the immunotherapeutic cell for cancer. Nagaraj S; Ziske C; Schmidt-Wolf IG Indian J Med Res; 2004 Apr; 119(4):133-8. PubMed ID: 15147117 [TBL] [Abstract][Full Text] [Related]
31. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Kurokawa T; Oelke M; Mackensen A Int J Cancer; 2001 Mar; 91(6):749-56. PubMed ID: 11275975 [TBL] [Abstract][Full Text] [Related]
32. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599 [TBL] [Abstract][Full Text] [Related]
33. Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy. Hradilova N; Sadilkova L; Palata O; Mysikova D; Mrazkova H; Lischke R; Spisek R; Adkins I PLoS One; 2017; 12(2):e0171539. PubMed ID: 28187172 [TBL] [Abstract][Full Text] [Related]
34. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612 [TBL] [Abstract][Full Text] [Related]
35. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nair SK; Heiser A; Boczkowski D; Majumdar A; Naoe M; Lebkowski JS; Vieweg J; Gilboa E Nat Med; 2000 Sep; 6(9):1011-7. PubMed ID: 10973321 [TBL] [Abstract][Full Text] [Related]
36. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination. Chambers B; Grufman P; Fredriksson V; Andersson K; Roseboom M; Laban S; Camps M; Wolpert EZ; Wiertz EJ; Offringa R; Ljunggren HG; van Hall T Cancer Res; 2007 Sep; 67(18):8450-5. PubMed ID: 17875682 [TBL] [Abstract][Full Text] [Related]
37. An ex vivo readout for evaluation of dendritic cell-induced autologous cytotoxic T lymphocyte responses against esophageal cancer. Milano F; Rygiel AM; Buttar N; Bergman JJ; Sondermeijer C; van Baal JW; ten Brinke A; Kapsenberg M; van Ham SM; Peppelenbosch MP; Krishnadath KK Cancer Immunol Immunother; 2007 Dec; 56(12):1967-77. PubMed ID: 17564704 [TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Hobo W; Strobbe L; Maas F; Fredrix H; Greupink-Draaisma A; Esendam B; de Witte T; Preijers F; Levenga H; van Rees B; Raymakers R; Schaap N; Dolstra H Cancer Immunol Immunother; 2013 Aug; 62(8):1381-92. PubMed ID: 23728352 [TBL] [Abstract][Full Text] [Related]
39. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis]. Pan JP; Weng YS; Wu QQ Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366 [TBL] [Abstract][Full Text] [Related]
40. [Cancer treatment by comprehensive regulation of anti-tumor immune network]. Kawakami Y Nihon Rinsho; 2010 Jun; 68(6):1094-9. PubMed ID: 20535961 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]